Teva price target raised to $20 from $13 at Barclays. Barclays analyst Douglas Tsao raised his price target for Teva Pharmaceutical to $20 citing improved fundamentals in generics. The analyst, however, keeps an Equal Weight rating on the shares. He wants better visibility on generic product launches before coming off the sidelines.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.